Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
International Journal of Medicinal Mushrooms
Импакт фактор: 1.423 5-летний Импакт фактор: 1.525 SJR: 0.431 SNIP: 0.716 CiteScore™: 2.6

ISSN Печать: 1521-9437
ISSN Онлайн: 1940-4344

Выпуски:
Том 22, 2020 Том 21, 2019 Том 20, 2018 Том 19, 2017 Том 18, 2016 Том 17, 2015 Том 16, 2014 Том 15, 2013 Том 14, 2012 Том 13, 2011 Том 12, 2010 Том 11, 2009 Том 10, 2008 Том 9, 2007 Том 8, 2006 Том 7, 2005 Том 6, 2004 Том 5, 2003 Том 4, 2002 Том 3, 2001 Том 2, 2000 Том 1, 1999

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushrooms.v7.i3.150
352 pages

Medicinal Mushroom Substances as Cancer Molecular Therapy

Jamal A. Mahajna
Migal, Galilee Technology Center, Cancer Drug Discovery Program, Kiryat Shmona; Galilee Institute for Applied Research, Nazareth
Majed Yassin
Institute of Evolution, University of Haifa, Mount Carmel, Haifa, Israel; Migal, Galilee Technology Center, Kiryat Shmona, Israel; Galilee Institute for Applied Research, Nazareth, Israel
Ben-Zion Zaidman
Institute of Evolution, University of Haifa, Mount Carmel, Haifa 31905, Israel; and Migal, Galilee Technology Center, Cancer Drug Discovery Program, P.O. Box 831, Kiryat Shmona 11016, Israel

Краткое описание

Medicinal mushrooms possess a variety of health promoting qualities as well as being a potential source of a variety of pharmaceuticals for some diseases, including cancer. Although most of the attention for their anticancer activity revolved around the activity of high-molecular-weight polysaccharides with no clear mechanism of action, our focus is on low-molecular-weight mushroom substances with a well-defined mechanism of action.
A neoplasm is an abnormal mass or colony of cells produced by a relatively autonomous new growth of tissue arising from the clonal expansion of a single cell that has undergone neoplastic transformation, which is usually accompanied by the loss of some specialized functions and the acquisition of new biological properties mediated by alteration in the expression or function of specific molecular targets. Our research interest on mushroom substances that specifically modulate molecular targets implicated in carcinogenesis, especially in chronic myelogenous leukemia (CML) and prostate cancer (PCa).
CML is a malignancy of pluripotent hematopoietic cells characterized by distinctive cytogenetic abnormality resulting in the creation of a p210 Bcr-Abl fusion protein with increased tyrosine kinase activity.
Imatinib is a potent inhibitor of Bcr-Abl and is used as standard therapy for CML. Unfortunately, clinical efficacy continuously decreases with the advancement of the disease. Secondary resistance is mostly due to the acquisition of point mutations in Bcr-Abl, which argues for the need of developing alternative inhibitors of Bcr-Abl.
Medicinal mushrooms exhibiting selective anti-CML activity were selected. Active mushroom substances induced apoptosis and erythroid differentiation in CML cells and caused a reduction in Bcr-Abl levels. Focusing on mushroom #540 and #514, we show that medicinal mushroom substances were effective in inhibiting auto-phosphorylation from wild types as well as from imatinib-resistance mutants of Bcr-Abl.
PCa is the second leading cause of death in Western men. Primary PCa is hormone dependent and is manageable by hormonal therapy. However, it rapidly develops into hormone-refractory tumors due to the accumulation of mutations in the androgen receptor (AR) or to the acquisition of alternative cellular pathways that support proliferation and inhibit apoptosis of PCa in androgen-independent mechanisms.
Whereas PCa is very common in Western countries, its levels are very low in several countries in Asia. Several reports linked Eastern diets and cancer occurrence, especially for PCa. Of special interest is the implication of several mushrooms in the prevention of PCa in Asia.
We evaluate the ability of mushroom substances extracted from our collection ot mushroom strains to interfere selectively with the activity of AR, the leading molecular target implicated in the development and maintenance of hormone-refractory PCa. Data showing anti-prostate cancer activity and the ability to modulate AR and other molecular targets will be presented.


Articles with similar content:

Secondary Metabolites from Edible and Medicinal Mushrooms as Molecular Therapy for Prostate Cancer
International Journal of Medicinal Mushrooms, Vol.7, 2005, issue 3
Jamal A. Mahajna, Ben-Zion Zaidman
New Dietary Supplements from Medicinal Mushrooms: Dr Myko San—A Registration Report
International Journal of Medicinal Mushrooms, Vol.13, 2011, issue 3
Ivan Jakopovich
Oncogene- and Tumor-Suppressor Gene-Related Proteins in Plants and Fungi
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 1-2
Peter Loidl, Adele Loidl
KAI1/CD82, Metastasis Suppressor Gene as a Therapeutic Target for Non-Small-Cell Lung Carcinoma
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 3
S. Niranjali Devaraj, Venugopal Vinod Prabhu
Epigenetic/Genetic Mismatch: Using Transdifferentiation as a Potential Cancer Therapy to Exploit the Cell Type Specificity of Cancer
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
Devasis Chatterjee, Andrew R. Mendelsohn, Jennifer L. Lei